Journal article
Enhanced Tropism of Species B1 Adenoviral-Based Vectors for Primary Human Airway Epithelial Cells
Molecular therapy. Methods & clinical development, Vol.14, pp.228-236
09/13/2019
DOI: 10.1016/j.omtm.2019.07.001
PMCID: PMC6690641
PMID: 31417941
Abstract
Adenoviruses are efficient vehicles for transducing airway epithelial cells. Human adenoviruses (Ads) are classified into seven species termed A–G. Most species use the coxsackie-adenovirus receptor (CAR) as a primary cellular receptor. Ad group B is notable because it is further divided into groups B1 and B2 and its members use CD46 or desmoglein 2 (DSG2) as cellular receptors. To date, human Ad types 2 and 5 have been the predominant choices for preclinical and clinical trials using Ad-based viral vectors in the airways. In this study, we screened 14 Ad types representing species C, B1, B2, D, and E. Using well-differentiated primary cultures of human airway epithelial cells (HAEs), we examined transduction efficiency. Based on GFP or nanoluciferase expression, multiple Ad types transduced HAEs as well as or better than Ad5. Ad3, Ad21, and Ad14 belong to species B and had notable transduction properties. We further examined the transduction properties of conditionally reprogrammed airway basal cells and primary basal cells from human lung donors. Again, the transduction efficiency of species B members outperformed the other types. These data suggest that adenoviral vectors based on species B transduce fully differentiated epithelial cells and progenitor cells in the human airways better than Ad5.
Details
- Title: Subtitle
- Enhanced Tropism of Species B1 Adenoviral-Based Vectors for Primary Human Airway Epithelial Cells
- Creators
- Ni Li - University of IowaAshley L. Cooney - University of IowaWenli Zhang - Witten/Herdecke UniversityAnja Ehrhardt - Witten/Herdecke UniversityPatrick L. Sinn - University of Iowa
- Resource Type
- Journal article
- Publication Details
- Molecular therapy. Methods & clinical development, Vol.14, pp.228-236
- DOI
- 10.1016/j.omtm.2019.07.001
- PMID
- 31417941
- PMCID
- PMC6690641
- NLM abbreviation
- Mol Ther Methods Clin Dev
- ISSN
- 2329-0501
- eISSN
- 2329-0501
- Publisher
- Elsevier Inc
- Grant note
- DOI: 10.13039/100000002, name: NIH, award: NIH P01 HL-51670, NIH P01 HL-091842, NIH R01 HL-133089, NIH R01 HL-105821; name: Center for Gene Therapy of Cystic Fibrosis, award: NIH P30 DK-054759; DOI: 10.13039/100000897, name: Cystic Fibrosis Foundation, award: SINN15XX0
- Language
- English
- Date published
- 09/13/2019
- Academic Unit
- Microbiology and Immunology; Pulmonary Medicine; Anatomy and Cell Biology; Stead Family Department of Pediatrics
- Record Identifier
- 9984297437502771
Metrics
8 Record Views